The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N05 | Psycholeptics | |
| 3 | N05A | Antipsychotics | |
| 4 | N05AB | Phenothiazines with piperazine structure | |
| 5 | N05AB03 | Perphenazine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 30 mg |
| PAREN - Parenteral | 10 mg |
| PAREN - Parenteral (depot) | 7 mg |
| Active Ingredient | Description | |
|---|---|---|
| Perphenazine |
Perphenazine is a depressant which blocks dopamine receptors in the central nervous system. It binds to dopamine D1 and D2 receptors and inhibits their activity. Its antiemetic action is mainly due to the inhibition of D2 receptors in the center of the vomiting. Perphenazine also binds to alpha adrenergic receptors and in conjunction with G proteins activate the phosphatidylinositol-calcium system. |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
